FindTrial
Sign In

Studying the role of 18FDG PET-CT in understanding the metabolism of lung cancers, including Adenocarcinoma and Squamous Cell Carcinoma.

18FDG PET-CT metabolic parameters in Adenocarcinoma and Squamous Cell Carcinoma of Lung. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/01/062021
Enrollment
48
Registered
2024-01-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C34- Malignant neoplasm of bronchus andlung

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

AIIMS Jodhpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age more than or equal to 18 years. 2. Diagnosed cases of Adenocarcinoma and Squamous Cell Carcinoma of lung.

Exclusion criteria

Exclusion criteria: 1. Pregnant and breastfeeding women. 2. Non-compliant patients.

Design outcomes

Primary

MeasureTime frame
This study will help us to understand the variation in glucose metabolism among cases of Adenocarcinoma and Squamous Cell Carcinoma of lung. Timepoint: After scan acquisition.—

Secondary

MeasureTime frame
This study may be beneficial in identifying the two common subtypes of Lung cancer on the basis of 18FDG PET-CT metabolic parameters. Timepoint: After scan acquisition.—

Countries

India

Contacts

Public ContactMehul Dulet

AIIMS, Jodhpur

rajesh.nmd@gmail.com02912831467

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026